

MATERIAL CHANGE REPORT

Pursuant to

SECTION 75(2) OF THE SECURITIES ACT (ONTARIO)
SECTION 85(1) OF THE SECURITIES ACT (BRITISH COLUMBIA)
SECTION 118(1) OF THE ALBERTA SECURITIES ACT (ALBERTA)

Item 1 - Reporting Issuer:

Meta Health Services Inc.
6891 Edwards Boulevard
Mississauga, Ontario
L5T 2T9

Item 2 - Date of Material Change:

October 29, 2004.

Item 3 – Press Release:

The press release attached hereto as Schedule “A” was issued in Toronto, Ontario on October 29, 2004.

Item 4 – Summary of Material Change:

The Company has announced today that following three years of significant success in the Canadian marketplace, Genzyme Canada Inc. and Theramed Corporation have decided to allow the promotion agreement for Thyrogen to expire on December 31, 2004, consistent with the planned end-date for this agreement. This decision will allow Genzyme Canada to develop the market for this brand utilizing their own resources and Theramed Corporation will be entitled to dedicate its own resources towards other priorities.

Item 5 – Full Description of Material Change:

The material change is fully described in the press release attached hereto as Schedule “A”.

Item 6 – Reliance on Confidentiality Sections of the Securities Acts:

Not applicable.

Item 7 - Omitted Information:

Not applicable.

Item 8 – Senior Officers:

For further information, please contact Robert Taylor, President and CEO of Meta at (905) 564-5009.

Item 9 – Statement of Senior Officer:

The foregoing accurately discloses the material change referred to herein.

DATED at Toronto this 2nd day of November, 2004.

META HEALTH SERVICES INC.

Per: “Robert Taylor”

Robert Taylor, President and CEO

IT IS AN OFFENCE FOR A PERSON TO MAKE A STATEMENT IN A DOCUMENT REQUIRED TO BE FILED OR FURNISHED UNDER THE ACT OR THIS REGULATION THAT AT THE TIME AND IN THE LIGHT OF THE CIRCUMSTANCES UNDER WHICH IT IS MADE, IS A MISREPRESENTATION.

Schedule "A"

**META HEALTH SERVICES INC.
NEWS RELEASE**

**AGREEMENT WITH GENZYME CANADA INC.
TO END DECEMBER 31, 2004**

TSX Venture Trading Symbol: MHS

October 29, 2004

Toronto: Meta Health Services Inc. announced today that following three years of significant success in the Canadian marketplace, Genzyme Canada Inc. and Theramed Corporation have decided to allow the promotion agreement for Thyrogen to expire on December 31, 2004, consistent with the planned end-date for this agreement. This decision will allow Genzyme Canada to develop the market for this brand utilizing their own resources and Theramed Corporation will be entitled to dedicate its own resources towards other priorities. Theramed and Genzyme will work closely over the next 2 months to ensure a seamless transition of responsibilities.

Meta Health Services Inc., through its wholly owned subsidiary **Theramed Corporation**, is a specialty pharmaceutical company focused on the management of niche pharmaceutical products for the Canadian market. Theramed has strategic alliances with a number of global pharmaceutical companies to commercialize their products within Canada.

For further information, please contact Robert Taylor, President and CEO of Meta at (905) 564-5009.

*The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this news release.*